Daniel Fernández-García

GEICAM - Spanish Breast Cancer Group

*This is an algorithmically generated author record based on publicly available information.

See Latest Publications

See Most Cited Publications

ORCID Profile

Google Scholar

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years

Instituto de Biología Molecular y Celular del Cáncer de Salamanca

Research Subjects

Research Interests

Daniel Fernández-García has a total of 203 co-authors. Here are the top co-authors by number of shared publications:

Antonio Antón
Hospital Universitario Miguel Servet, Zaragoza, Spain
129 shared publications
Begoña Bermejo
Hospital Clínico Universitario de Valencia, Valencia, Spain
129 shared publications
Christoph Zielinski
Medical Oncology, Central European Cancer Center, Wiener Privatklinik Hospital, Vienna, Austria
129 shared publications
Eva Ciruelos
Medical Oncology Department, Hospital 12 de Octubre, Madrid, Spain; Instituto de Investigación Sanitaria Hospital 12 de Octubre (Imas12), Madrid, Spain; SOLTI Cancer Research Group, Barcelona, Spain
129 shared publications
Javier Pascual
Hospital Universitario Virgen de la Victoria, Malaga, Spain
129 shared publications
Jesus Herranz
GEICAM, Spanish Breast Cancer Group, Madrid, Spain
129 shared publications

Latest Publications

Sort by

Open Access
Website
Google Scholar
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S9 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
by Javier Pascual, Miguel Gil-Gil, Paula Proszek, Christoph Zielinski, Alistair Reay, Manuel Ruiz-Borrego, Rosalind Cutts, Eva M. Ciruelos Gil, Andrew Feber, Montserrat Muñoz-Mateu, et al.
Supplementary Table 9. Summary of PFS results for ESR1 and PIK3CA mutations. Cox regression univariate and multivariate analysis.
Website
Google Scholar
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Table S9 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
by Javier Pascual, Miguel Gil-Gil, Paula Proszek, Christoph Zielinski, Alistair Reay, Manuel Ruiz-Borrego, Rosalind Cutts, Eva M. Ciruelos Gil, Andrew Feber, Montserrat Muñoz-Mateu, et al.
Supplementary Table 9. Summary of PFS results for ESR1 and PIK3CA mutations. Cox regression univariate and multivariate analysis.
Open Access
Website
Google Scholar
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S11 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
by Javier Pascual, Miguel Gil-Gil, Paula Proszek, Christoph Zielinski, Alistair Reay, Manuel Ruiz-Borrego, Rosalind Cutts, Eva M. Ciruelos Gil, Andrew Feber, Montserrat Muñoz-Mateu, et al.
Supplementary Table 11. Baseline characteristics comparison between population with CDR calculation (n=120) vs non-CDR population (n=81).
Website
Google Scholar
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Table S11 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
by Javier Pascual, Miguel Gil-Gil, Paula Proszek, Christoph Zielinski, Alistair Reay, Manuel Ruiz-Borrego, Rosalind Cutts, Eva M. Ciruelos Gil, Andrew Feber, Montserrat Muñoz-Mateu, et al.
Supplementary Table 11. Baseline characteristics comparison between population with CDR calculation (n=120) vs non-CDR population (n=81).
Open Access
Website
Google Scholar
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from CCNE1 and PLK1 Mediate Resistance to Palbociclib in HR+/HER2− Metastatic Breast Cancer
by Ángel Guerrero-Zotano, Stefania Belli, Christoph Zielinski, Miguel Gil-Gil, Antonio Fernandez-Serra, Manuel Ruiz-Borrego, Eva Maria Ciruelos Gil, Javier Pascual, Montserrat Muñoz-Mateu, Begoña Bermejo, et al.
Analysis of gene expression associated with treatment benefit
Website
Google Scholar
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Figure S5 from CCNE1 and PLK1 Mediate Resistance to Palbociclib in HR+/HER2− Metastatic Breast Cancer
by Ángel Guerrero-Zotano, Stefania Belli, Christoph Zielinski, Miguel Gil-Gil, Antonio Fernandez-Serra, Manuel Ruiz-Borrego, Eva Maria Ciruelos Gil, Javier Pascual, Montserrat Muñoz-Mateu, Begoña Bermejo, et al.
Analysis of gene expression associated with treatment benefit
Open Access
Website
Google Scholar
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from CCNE1 and PLK1 Mediate Resistance to Palbociclib in HR+/HER2− Metastatic Breast Cancer
by Ángel Guerrero-Zotano, Stefania Belli, Christoph Zielinski, Miguel Gil-Gil, Antonio Fernandez-Serra, Manuel Ruiz-Borrego, Eva Maria Ciruelos Gil, Javier Pascual, Montserrat Muñoz-Mateu, Begoña Bermejo, et al.
Progression Free Survival analysis on CCNE1 expression levels under palbociclib plus ET treatment
Website
Google Scholar
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Figure S4 from CCNE1 and PLK1 Mediate Resistance to Palbociclib in HR+/HER2− Metastatic Breast Cancer
by Ángel Guerrero-Zotano, Stefania Belli, Christoph Zielinski, Miguel Gil-Gil, Antonio Fernandez-Serra, Manuel Ruiz-Borrego, Eva Maria Ciruelos Gil, Javier Pascual, Montserrat Muñoz-Mateu, Begoña Bermejo, et al.
Progression Free Survival analysis on CCNE1 expression levels under palbociclib plus ET treatment
Open Access
Website
Google Scholar
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from CCNE1 and PLK1 Mediate Resistance to Palbociclib in HR+/HER2− Metastatic Breast Cancer
by Ángel Guerrero-Zotano, Stefania Belli, Christoph Zielinski, Miguel Gil-Gil, Antonio Fernandez-Serra, Manuel Ruiz-Borrego, Eva Maria Ciruelos Gil, Javier Pascual, Montserrat Muñoz-Mateu, Begoña Bermejo, et al.
List of 51 genes differentially expressed in tumors, grouped by sensitive or refractory to palbociclib plus ET. Controlling the FDR at 5% with the q-value method (SAM)
Website
Google Scholar
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Table S1 from CCNE1 and PLK1 Mediate Resistance to Palbociclib in HR+/HER2− Metastatic Breast Cancer
by Ángel Guerrero-Zotano, Stefania Belli, Christoph Zielinski, Miguel Gil-Gil, Antonio Fernandez-Serra, Manuel Ruiz-Borrego, Eva Maria Ciruelos Gil, Javier Pascual, Montserrat Muñoz-Mateu, Begoña Bermejo, et al.
List of 51 genes differentially expressed in tumors, grouped by sensitive or refractory to palbociclib plus ET. Controlling the FDR at 5% with the q-value method (SAM)
Open Access
Website
Google Scholar
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
by Javier Pascual, Miguel Gil-Gil, Paula Proszek, Christoph Zielinski, Alistair Reay, Manuel Ruiz-Borrego, Rosalind Cutts, Eva M. Ciruelos Gil, Andrew Feber, Montserrat Muñoz-Mateu, et al.
Supplementary Figure 4. OS analysis in baseline population (C1D1) on ESR1 and PIK3CA mutations, within the population with any detectable mutation (N=146).
Website
Google Scholar
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Figure S4 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
by Javier Pascual, Miguel Gil-Gil, Paula Proszek, Christoph Zielinski, Alistair Reay, Manuel Ruiz-Borrego, Rosalind Cutts, Eva M. Ciruelos Gil, Andrew Feber, Montserrat Muñoz-Mateu, et al.
Supplementary Figure 4. OS analysis in baseline population (C1D1) on ESR1 and PIK3CA mutations, within the population with any detectable mutation (N=146).
Open Access
Website
Google Scholar
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
by Javier Pascual, Miguel Gil-Gil, Paula Proszek, Christoph Zielinski, Alistair Reay, Manuel Ruiz-Borrego, Rosalind Cutts, Eva M. Ciruelos Gil, Andrew Feber, Montserrat Muñoz-Mateu, et al.
Supplementary Table 2. Complete table results for all patients (n=201) involved in baseline (C1D1) analysis.
Website
Google Scholar
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Table S2 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
by Javier Pascual, Miguel Gil-Gil, Paula Proszek, Christoph Zielinski, Alistair Reay, Manuel Ruiz-Borrego, Rosalind Cutts, Eva M. Ciruelos Gil, Andrew Feber, Montserrat Muñoz-Mateu, et al.
Supplementary Table 2. Complete table results for all patients (n=201) involved in baseline (C1D1) analysis.
Open Access
Website
Google Scholar
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S9 from CCNE1 and PLK1 Mediate Resistance to Palbociclib in HR+/HER2− Metastatic Breast Cancer
by Ángel Guerrero-Zotano, Stefania Belli, Christoph Zielinski, Miguel Gil-Gil, Antonio Fernandez-Serra, Manuel Ruiz-Borrego, Eva Maria Ciruelos Gil, Javier Pascual, Montserrat Muñoz-Mateu, Begoña Bermejo, et al.
Drug combination studies in MCF7, T47D and T47D-FPR cells
Website
Google Scholar
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Figure S9 from CCNE1 and PLK1 Mediate Resistance to Palbociclib in HR+/HER2− Metastatic Breast Cancer
by Ángel Guerrero-Zotano, Stefania Belli, Christoph Zielinski, Miguel Gil-Gil, Antonio Fernandez-Serra, Manuel Ruiz-Borrego, Eva Maria Ciruelos Gil, Javier Pascual, Montserrat Muñoz-Mateu, Begoña Bermejo, et al.
Drug combination studies in MCF7, T47D and T47D-FPR cells
Open Access
Website
Google Scholar
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S10 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
by Javier Pascual, Miguel Gil-Gil, Paula Proszek, Christoph Zielinski, Alistair Reay, Manuel Ruiz-Borrego, Rosalind Cutts, Eva M. Ciruelos Gil, Andrew Feber, Montserrat Muñoz-Mateu, et al.
Supplementary Table 10. Summary of OS results for ESR1 and PIK3CA mutations. Cox regression univariate and multivariate analysis.
Website
Google Scholar
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Table S10 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
by Javier Pascual, Miguel Gil-Gil, Paula Proszek, Christoph Zielinski, Alistair Reay, Manuel Ruiz-Borrego, Rosalind Cutts, Eva M. Ciruelos Gil, Andrew Feber, Montserrat Muñoz-Mateu, et al.
Supplementary Table 10. Summary of OS results for ESR1 and PIK3CA mutations. Cox regression univariate and multivariate analysis.
Open Access
Website
Google Scholar
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from CCNE1 and PLK1 Mediate Resistance to Palbociclib in HR+/HER2− Metastatic Breast Cancer
by Ángel Guerrero-Zotano, Stefania Belli, Christoph Zielinski, Miguel Gil-Gil, Antonio Fernandez-Serra, Manuel Ruiz-Borrego, Eva Maria Ciruelos Gil, Javier Pascual, Montserrat Muñoz-Mateu, Begoña Bermejo, et al.
Generation and characterization of ER+ breast cancer cell lines resistant to palbociclib alone or in combination with fulvestrant
Website
Google Scholar
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Figure S7 from CCNE1 and PLK1 Mediate Resistance to Palbociclib in HR+/HER2− Metastatic Breast Cancer
by Ángel Guerrero-Zotano, Stefania Belli, Christoph Zielinski, Miguel Gil-Gil, Antonio Fernandez-Serra, Manuel Ruiz-Borrego, Eva Maria Ciruelos Gil, Javier Pascual, Montserrat Muñoz-Mateu, Begoña Bermejo, et al.
Generation and characterization of ER+ breast cancer cell lines resistant to palbociclib alone or in combination with fulvestrant

Show all